Collegium Pharma Files Definitive Proxy Statement

TL;DR

Collegium Pharma just dropped its proxy statement - shareholders vote soon on company matters.

AI Summary

Collegium Pharmaceutical, Inc. filed a Definitive Proxy Statement (DEFA14A) on April 5, 2024. This filing is a standard proxy statement, indicating it's related to the company's annual meeting or a special meeting where shareholders will vote on corporate matters. The document details information for shareholders regarding the upcoming meeting and voting procedures.

Why It Matters

This filing is crucial for shareholders as it outlines the agenda for upcoming votes, including potential executive compensation, board elections, or other significant corporate decisions that could impact the company's direction and shareholder value.

Risk Assessment

Risk Level: low — This is a routine regulatory filing (DEFA14A) and does not inherently contain new financial risks or material non-public information.

Key Players & Entities

• COLLEGIUM PHARMACEUTICAL, INC. (company) — Registrant
• 0001104659-24-044247 (filing_id) — Accession Number
• 20240405 (date) — Filing Date
• 001-37372 (company_id) — SEC File Number
• 100 TECHNOLOGY CENTER DRIVE (address) — Business Address
• STOUGHTON (city) — Business Address City
• MA (state) — Business Address State
• 02072 (zip_code) — Business Address Zip

FAQ

Filing Documents

• tm248754d4_defa14a.htm (DEFA14A) — 17KB
• tm248754d4_defa14aimg001.jpg (GRAPHIC) — 380KB
• tm248754d4_defa14aimg002.jpg (GRAPHIC) — 264KB
• 0001104659-24-044247.txt ( ) — 905KB

From the Filing

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ​ Filed by a Party other than the Registrant ​ Check the appropriate box: ​ Preliminary Proxy Statement ​ ​ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ​ ​ Definitive Proxy Statement ​ ​ Definitive Additional Materials ​ ​ Soliciting Material under §240.14a-12 ​ COLLEGIUM PHARMACEUTICAL, INC. (Name of Registrant as Specified in Its Charter) ​ ​ (Name of Person(s) Filing Proxy Statement, if Other Than the Registrant) ​ Payment of Filing Fee (Check all boxes that apply): No fee required Fee paid previously with preliminary materials Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11 Step 1: Go to https://www.envisionreports.com/COPI. Step 2: Click on Cast Your Vote or Request Materials. Step 3: Follow the instructions on the screen to log in. www.envisionreports.com/COPI Online Go to https://www.envisionreports.com/COPI or scan the QR code — login details are located in the shaded bar below. The Sample Company Shareholder Meeting Notice 03YSOB + + Important Notice Regarding the Availability of Proxy Materials for the Collegium Pharmaceutical, Inc. Meeting to be Held on May 16, 2024 Under Securities and Exchange Commission rules, you are receiving this notice that the proxy materials for the annual shareholders’ meeting are available on the Internet. Follow the instructions below to view the materials and vote online or request a copy. The items to be voted on and location of the annual meeting are on the reverse side. Your vote is important! This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. We encourage you to access and review all of the important information contained in the proxy materials before voting. The proxy statement and annual report to shareholders are available at: Obtaining a Copy of the Proxy Materials – If you want to receive a copy of these documents, you must request one. There is no charge to you for requesting a copy. Please make your request for a copy as instructed on the reverse side on or before May 3, 2024 to facilitate timely delivery. 2 N O T Easy Online Access — View your proxy materials and vote. When you go online, you can also help the environment by consenting to receive electronic delivery of future materials. Step 4: Make your selections as instructed on each screen for your delivery preferences. Step 5: Vote your shares. MMMMMMMMMMMM M M M M M M M M M MR A SAMPLE DESIGNATION (IF ANY) ADD 1 ADD 2 ADD 3 ADD 4 ADD 5 ADD 6 ENDORSEMENT_LINE______________ SACKPACK_____________ 1234 5678 9012 345 C 1234567890 C O Y MMMMMMM 0 0 0 0 0 1 Here’s how to order a copy of the proxy materials and select delivery preferences: Current and future delivery requests can be submitted using the options below. If you request an email copy, you will receive an email with a link to the current meeting materials. PLEASE NOTE: You must use the number in the shaded bar on the reverse side when requesting a copy of the proxy materials. — Internet – Go to www.envisionreports.com/COPI. Click Cast Your Vote or Request Materials. — Phone – Call us free of charge at 1-866-641-4276. — Email – Send an email to investorvote@computershare.com with “Proxy Materials Collegium Pharmaceutical, Inc.” in the subject line. Include your full name and address, plus the number located in the shaded bar on the reverse side, and state that you want a paper copy of the meeting materials. To facilitate timely delivery, all requests for a paper copy of proxy materials must be received by May 3, 2024. Collegium Pharmaceutical, Inc.’s Annual Meeting of Shareholders will be held on May 16, 2024 virtually via live webcast meetnow.global/MWVTLQP at 8:30 a.m. Eastern Time. Proposals to be voted on at the meeting are listed below along with the Board of Directors’ recommendations. The Board of Directors recommends a vote FOR all the nominees listed and FOR Proposals 2 and 3: 1. Election of Rita Balice-Gordon, Ph.D., Garen Bohlin, Joseph Ciaffoni, John Fallon, M.D., John Freund, M.D., Michael Heffernan, R.Ph., Neil McFarlane, Gwen Melincoff and Gino Santini as directors to hold office until the 2025 Annual Meeting. 2. Approval of, on an advisory basis, the compensation of the Company’s named executive officers. 3.

View Full Filing

View this DEFA14A filing on SEC EDGAR